Tumor-derived interferons (IFNs) can enhance the expression of antigen presentation genes, promote the recruitment of dendritic cells (DCs) and CD8+ T cells into the tumor microenvironment through autocrine and paracrine signaling pathway, and thereby enhance the therapeutic efficacy of immunotherapy [5, 6]. This evidence concerns the gene CD8A and neoplasm.